Cargando…

Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection

SIMPLE SUMMARY: Prostate cancer (PCa) nodal staging does not account for tumor burden within the lymph nodes (LNs). In this retrospective single institution/single surgeon study, we assessed the significance of LN tumor burden in pN1 PCa patients after undergoing robotic-assisted radical prostatecto...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Josh, Chang, Shu-Ching, Choe, Jane, Grunkemeier, Gary L., Hanes, Douglas A., Krasne, David, Hoon, Dave S. B., Wilson, Timothy G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378308/
https://www.ncbi.nlm.nih.gov/pubmed/37509368
http://dx.doi.org/10.3390/cancers15143707
_version_ 1785079733282668544
author Gottlieb, Josh
Chang, Shu-Ching
Choe, Jane
Grunkemeier, Gary L.
Hanes, Douglas A.
Krasne, David
Hoon, Dave S. B.
Wilson, Timothy G.
author_facet Gottlieb, Josh
Chang, Shu-Ching
Choe, Jane
Grunkemeier, Gary L.
Hanes, Douglas A.
Krasne, David
Hoon, Dave S. B.
Wilson, Timothy G.
author_sort Gottlieb, Josh
collection PubMed
description SIMPLE SUMMARY: Prostate cancer (PCa) nodal staging does not account for tumor burden within the lymph nodes (LNs). In this retrospective single institution/single surgeon study, we assessed the significance of LN tumor burden in pN1 PCa patients after undergoing robotic-assisted radical prostatectomy with extended pelvic lymph node dissection. Consistent with prior reports, LN tumor burden was found to be significantly associated with biochemical recurrence-free survival (BRFS). This study was the first to report on the significance of the anatomical location of tumor deposits within the LN, as well as the quantified extent of extranodal extension (ENE). Likely due to sample size, the anatomical location within the LN and ENE did not show significant association with BRFS. We emphasize that PCa nodal staging and/or post-operative clinical nomograms should account for LN tumor burden. ABSTRACT: Background: Prostate cancer (PCa) nodal staging does not account for lymph node (LN) tumor burden. The LN anatomical compartment involved with the tumor or the quantified extent of extranodal extension (ENE) have not yet been studied in relation to biochemical recurrence-free survival (BRFS). Methods: Histopathological slides of 66 pN1 PCa patients who underwent extended pelvic lymph node dissection were reviewed. We recorded metrics to quantify LN tumor burden. We also characterized the LN anatomical compartments involved and quantified the extent of ENE. Results: The median follow-up time was 38 months. The median number of total LNs obtained per patient was 30 (IQR 23–37). In the risk-adjusted cox regression model, the following variables were associated with BRFS: mean size of the largest LN deposit per patient (log2: adjusted hazard ratio (aHR) = 1.91, p < 0.001), the mean total span of all LN deposits per patient (2.07, p < 0.001), and the mean percent surface area of the LN involved with the tumor (1.58, p < 0.001). There was no significant BRFS association for the LN anatomical compartment or the quantified extent of ENE. Conclusion: LN tumor burden is associated with BRFS. The LN anatomical compartments and the quantified extent of ENE did not show significant association with BRFS.
format Online
Article
Text
id pubmed-10378308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103783082023-07-29 Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection Gottlieb, Josh Chang, Shu-Ching Choe, Jane Grunkemeier, Gary L. Hanes, Douglas A. Krasne, David Hoon, Dave S. B. Wilson, Timothy G. Cancers (Basel) Article SIMPLE SUMMARY: Prostate cancer (PCa) nodal staging does not account for tumor burden within the lymph nodes (LNs). In this retrospective single institution/single surgeon study, we assessed the significance of LN tumor burden in pN1 PCa patients after undergoing robotic-assisted radical prostatectomy with extended pelvic lymph node dissection. Consistent with prior reports, LN tumor burden was found to be significantly associated with biochemical recurrence-free survival (BRFS). This study was the first to report on the significance of the anatomical location of tumor deposits within the LN, as well as the quantified extent of extranodal extension (ENE). Likely due to sample size, the anatomical location within the LN and ENE did not show significant association with BRFS. We emphasize that PCa nodal staging and/or post-operative clinical nomograms should account for LN tumor burden. ABSTRACT: Background: Prostate cancer (PCa) nodal staging does not account for lymph node (LN) tumor burden. The LN anatomical compartment involved with the tumor or the quantified extent of extranodal extension (ENE) have not yet been studied in relation to biochemical recurrence-free survival (BRFS). Methods: Histopathological slides of 66 pN1 PCa patients who underwent extended pelvic lymph node dissection were reviewed. We recorded metrics to quantify LN tumor burden. We also characterized the LN anatomical compartments involved and quantified the extent of ENE. Results: The median follow-up time was 38 months. The median number of total LNs obtained per patient was 30 (IQR 23–37). In the risk-adjusted cox regression model, the following variables were associated with BRFS: mean size of the largest LN deposit per patient (log2: adjusted hazard ratio (aHR) = 1.91, p < 0.001), the mean total span of all LN deposits per patient (2.07, p < 0.001), and the mean percent surface area of the LN involved with the tumor (1.58, p < 0.001). There was no significant BRFS association for the LN anatomical compartment or the quantified extent of ENE. Conclusion: LN tumor burden is associated with BRFS. The LN anatomical compartments and the quantified extent of ENE did not show significant association with BRFS. MDPI 2023-07-21 /pmc/articles/PMC10378308/ /pubmed/37509368 http://dx.doi.org/10.3390/cancers15143707 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gottlieb, Josh
Chang, Shu-Ching
Choe, Jane
Grunkemeier, Gary L.
Hanes, Douglas A.
Krasne, David
Hoon, Dave S. B.
Wilson, Timothy G.
Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title_full Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title_fullStr Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title_full_unstemmed Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title_short Characterization of Lymph Node Tumor Burden in Node-Positive Prostate Cancer Patients after Robotic-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
title_sort characterization of lymph node tumor burden in node-positive prostate cancer patients after robotic-assisted radical prostatectomy with extended pelvic lymph node dissection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378308/
https://www.ncbi.nlm.nih.gov/pubmed/37509368
http://dx.doi.org/10.3390/cancers15143707
work_keys_str_mv AT gottliebjosh characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT changshuching characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT choejane characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT grunkemeiergaryl characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT hanesdouglasa characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT krasnedavid characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT hoondavesb characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection
AT wilsontimothyg characterizationoflymphnodetumorburdeninnodepositiveprostatecancerpatientsafterroboticassistedradicalprostatectomywithextendedpelviclymphnodedissection